GPs could face a rise in prescribing and monitoring work under draft NICE guidelines recommending earlier use of newer type 2 ...

New recommendations suggest holding back on SGLT2 inhibitors and GLP-1s among those at a lower risk for cardiovascular or ...

Empowering choice in the pharmacological management of type 2 diabetes One in nine people worldwide lives with diabetes, with 90% affected by type 2 diabetes.1 Despite ongoing advances in therapy and ...

Millions of people are set to benefit from earlier access to newer type 2 diabetes treatments – the biggest shake-up in care for a decade – as part of NICE’s commitment to re-evaluate priority ...

Recent research challenges the long-held belief that all sugars equally contribute to type 2 diabetes. The source of sugar ...

Type 2 diabetes (T2D) has become one of the leading chronic diseases worldwide in terms of both incidence and mortality.

Potential game-changer' could save the NHS billions and prevent tens of thousands of heart attacks and strokes ...

A separate three-day assessment using continuous glucose monitoring found that, in participants with type 2 diabetes, ...

With its modular FlexBrim™, all-day comfort features, and full ANSI/ISEA Type II compliance, Bullard’s latest helmet sets a new benchmark in adaptive head protection.

In patients with type 2 diabetes (T2D), treatment with oral semaglutide demonstrated a modest but significant reduction in ...